← FDA DRUG APPROVALS

FDA ANDA · ANDA061653

TETREX

Sponsor: BRISTOL

APPLICATION
ANDA061653
TYPE
ANDA
ORIGINAL APPROVAL
1972-06-20
LATEST ACTION
1972-06-20
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TETREXDiscontinued
TETRACYCLINE PHOSPHATE COMPLEX EQ 100MG HYDROCHLORIDE · CAPSULE · ORAL
TETREXDiscontinued
TETRACYCLINE PHOSPHATE COMPLEX EQ 250MG HYDROCHLORIDE · CAPSULE · ORAL
TETREXDiscontinued
TETRACYCLINE PHOSPHATE COMPLEX EQ 500MG HYDROCHLORIDE · CAPSULE · ORAL

Approval history

1972-06-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →